Impact of Cardio-Selective Beta-Blockers on Infarct Size After Acute Myocardial Infarction
NCT ID: NCT07293832
Last Updated: 2025-12-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
100 participants
OBSERVATIONAL
2024-11-13
2026-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Purpose: The present study aims to investigate, whether the early intravenous administration of landiolol, a highly cardioselective b-blocker, reduces the extent of the necrotic area after ST-elevation myocardial infarction (STEMI).
Methods: This prospective observational cohort study will enroll patients presenting with STEMI, who undergo primary PCI and receive either intravenous landiolol or standard oral β-blocker therapy, in accordance with current European Society of Cardiology (ESC) guidelines. Eligibility will be determined by predefined inclusion and exclusion criteria. Treatment selection will be based solely on the clinical judgment of the attending cardiologist, without randomization.
Results: Final infarct size will be quantified by cardiac magnetic resonance imaging (CMR) performed at least three months after the STEMI to minimize edema-related overestimation. Myocardial function will be assessed during hospitalization using transthoracic echocardiography, including measurement of global longitudinal strain (GLS). Additional data will include serial high-sensitivity troponin and creatine phosphokinase (CPK) measurements, 24-hour continuous electrocardiographic monitoring for arrhythmia burden, and predefined safety outcomes collected throughout hospitalization.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intravenous BB (receiving landiolol) or p.o. BB
STEMI patients receiving beta-blocker
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with electrocardiogram showing ST-segment elevation ≥2 mm in 2 or more contiguous leads for more than 30 minutes
* Estimated time from symptom onset to reperfusion ≤12 hours
* Patients scheduled to undergo primary angioplasty
* Patients who have signed a consent form
Exclusion Criteria
* Patients with a previous myocardial infarction
* Persistent systolic blood pressure \<90 mmHg
* Persistent heart rate \<55 beats per minute
* Patients with Killip class III (acute pulmonary edema) or IV (cardiogenic shock) on initial examination
* 12-lead electrocardiogram with PR interval \>200 milliseconds
* 12-lead electrocardiogram showing second- or third-degree atrioventricular block
* Bronchospasm requiring bronchodilator treatment
* Possible pregnancy or postpartum period
* Inability or refusal to sign the consent form
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aristotle University Of Thessaloniki
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nikolaos Fragakis
Professor of Cardiology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nikolaos Fragakis, Professor fo Cardiology, PhD
Role: PRINCIPAL_INVESTIGATOR
Aristotle University Of Thessaloniki
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hippokration General Hospital of Thessaloniki
Thessaloniki, Thessaloniki, Greece
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Athina Nasoufidou, MD, MSc, PhDc
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Nasoufidou A, Bantidos MG, Stachteas P, Moysidis DV, Mitsis A, Fyntanidou B, Kouskouras K, Karagiannidis E, Karamitsos T, Kassimis G, Fragakis N. The Role of Landiolol in Coronary Artery Disease: Insights into Acute Coronary Syndromes, Stable Coronary Artery Disease and Computed Tomography Coronary Angiography. J Clin Med. 2025 Jul 23;14(15):5216. doi: 10.3390/jcm14155216.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
22/28-3-2023_5123
Identifier Type: -
Identifier Source: org_study_id